CPC A61K 31/713 (2013.01) [A61K 31/4439 (2013.01); A61K 31/506 (2013.01); A61K 31/711 (2013.01); A61K 31/7105 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] | 9 Claims |
1. A method of treating a FOXO3-associated cancer in a subject who is resistant to a phosphoinositide 3-kinase (PI3K) inhibitor monotherapy, comprising:
(a) sensitizing the subject to the PI3K inhibitor, wherein the sensitizing comprises administering to the subject an effective amount of a 3-phosphoinositide dependent protein kinase-1 (PDK1) inhibitor, a serine/threonine-protein kinase (SGK1) inhibitor, or a combination thereof; and
(b) administering to the subject an effective amount of the PI3K inhibitor, wherein the PI3K inhibitor is BYL719 (apelisib), the PDK1 inhibitor is GSK2334470 or a nucleic acid that specifically binds to a nucleic acid encoding PDK1 and reduces PDK1 activity and/or expression, and the SGK1 inhibitor is a nucleic acid that specifically binds to a nucleic acid encoding SGK1 and reduces SGK1 activity and/or expression or a small molecule comprising a pyrazolo(3,4-b)pyrazine head.
|